OBJECTIVES: To determine the safety and immunogenicity of the conjugate pneumococcal vaccine (PCV7) in pediatric solid organ transplant recipients. PATIENTS AND METHODS: Pediatric solid organ transplant recipients were prospectively enrolled at > or =4 months following transplantation. Eligible pneumococcal vaccine-naive subjects received 3 doses of PCV7 at 8 week intervals, followed 8 weeks later by a dose of the 23-valent vaccine (PV23). Serology was done at baseline, 8 weeks following doses 2 and 3 of PCV7 and 8-12 weeks after PV23. Repeated measures analyses were done using SAS 9. RESULTS: Eighty-one recipients commenced immunization at a median age of 7.8 (0.6-17.5) years and a median time from transplantation to immunization of 1.3 (0.3-6.0) years. There were 31 heart, 18 liver, 5 lung, and 27 kidney recipients. Reported adverse events following vaccine doses included local reactions (PCV7: PV23 = 19%:16%) and fever (PCV7: PV23 = 3.8%:4.9%) and there were no serious reactions. Two doses of PCV7 induced > or =2 fold increases in geometric mean concentrations (GMCs) in all organ groups. Cardiac and lung recipients demonstrated additional benefit from a third dose of PCV7. The cardiac recipients showed most benefit from boosting with PV23 with significant increases in GMC's (P < or = 0.008). The time of initiation of the vaccine strategy posttransplantation predicted seroprotection. CONCLUSION: PCV7 was safe and immunogenic in solid organ recipients. Three doses of this vaccine appear beneficial for selected organ groups. PV23 when administered at >/=1 year posttransplantation was useful in boosting antibody responses in patient groups demonstrating lower rates of responsiveness.
OBJECTIVES: To determine the safety and immunogenicity of the conjugate pneumococcal vaccine (PCV7) in pediatric solid organ transplant recipients. PATIENTS AND METHODS: Pediatric solid organ transplant recipients were prospectively enrolled at > or =4 months following transplantation. Eligible pneumococcal vaccine-naive subjects received 3 doses of PCV7 at 8 week intervals, followed 8 weeks later by a dose of the 23-valent vaccine (PV23). Serology was done at baseline, 8 weeks following doses 2 and 3 of PCV7 and 8-12 weeks after PV23. Repeated measures analyses were done using SAS 9. RESULTS: Eighty-one recipients commenced immunization at a median age of 7.8 (0.6-17.5) years and a median time from transplantation to immunization of 1.3 (0.3-6.0) years. There were 31 heart, 18 liver, 5 lung, and 27 kidney recipients. Reported adverse events following vaccine doses included local reactions (PCV7: PV23 = 19%:16%) and fever (PCV7: PV23 = 3.8%:4.9%) and there were no serious reactions. Two doses of PCV7 induced > or =2 fold increases in geometric mean concentrations (GMCs) in all organ groups. Cardiac and lung recipients demonstrated additional benefit from a third dose of PCV7. The cardiac recipients showed most benefit from boosting with PV23 with significant increases in GMC's (P < or = 0.008). The time of initiation of the vaccine strategy posttransplantation predicted seroprotection. CONCLUSION:PCV7 was safe and immunogenic in solid organ recipients. Three doses of this vaccine appear beneficial for selected organ groups. PV23 when administered at >/=1 year posttransplantation was useful in boosting antibody responses in patient groups demonstrating lower rates of responsiveness.
Authors: Britta Höcker; Martin Aguilar; Paul Schnitzler; Lars Pape; Martin Bald; Jens König; Stephen D Marks; Gurkan Genc; Anja Büscher; Markus J Kemper; Heiko Billing; Martin Pohl; Luca Dello Strologo; Nicholas J A Webb; Susanne Rieger; Annette Mankertz; Kai Krupka; Thomas Bruckner; Alexander Fichtner; Burkhard Tönshoff Journal: Pediatr Nephrol Date: 2018-01-10 Impact factor: 3.714
Authors: Hannah M Garcia Garrido; Albert Vollaard; Geert R D'Haens; Phyllis I Spuls; Frederike J Bemelman; Michael W Tanck; Godelieve J de Bree; Bob Meek; Martin P Grobusch; Abraham Goorhuis Journal: Vaccines (Basel) Date: 2022-05-17
Authors: Kathryn Malone; Stephanie Clark; Jo Ann Palmer; Sonya Lopez; Madhura Pradhan; Susan Furth; Jason Kim; Brian Fisher; Benjamin Laskin Journal: Pediatr Transplant Date: 2016-06-22